Biotechnology 

Envision Energy Earns World's First ISCC PLUS Certificate for Green Ammonia with GHG Metrics

Envision Energy, a global leader in green technology, announced that its Chifeng Hydrogen Net Zero Industrial Park has been officially awarded the ISCC Plus certification, becoming the first project worldwide to receive...

Envision Energy Earns World's First ISCC PLUS Certificate for Green Ammonia with GHG Metrics
Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation

Angel Yeast (600298.SH) recently released its 2024 Sustainability (ESG) Report, providing in-depth insights into the company's thoughts and actions towards sustainable development management. The report highlights...

Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a...

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The...

10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025
LevEllis, Inc. Announces the Launch of PROVOQUE™: A Revolutionary Regenerative Skincare Serum

LevEllis, Inc. a pioneering skincare company founded by renowned surgeon and molecular biologist, Laura Ellis, MD, and guided by a distinguished scientific advisory board, is excited to announce the official launch of...

LevEllis, Inc. Announces the Launch of PROVOQUE™: A Revolutionary Regenerative Skincare Serum
Canary Speech Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity

Canary Speech, the leading AI-powered voice biomarker health tech company, today announced its Canary Speech Technology and Services Platform residing at Azure Cloud Services (Azure) has earned certified status by HITRUST...

Canary Speech Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity
BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director

BrainXell, Inc., a leading biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, announces the appointment of Katherine Vega Stultz as its new Chief Executive Officer and Board...

BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director
Diagnostics Transformed: $37 Billion Immunoassay Market Evolves with AI, Miniaturization, and POC Growth, reports Kalorama Information

Kalorama Information, a leading healthcare market intelligence firm, has published a comprehensive new report, Global Immunoassay Market: Trends, Technologies, and Growth Opportunities, 2025. The report provides an...

Diagnostics Transformed: $37 Billion Immunoassay Market Evolves with AI, Miniaturization, and POC Growth, reports Kalorama Information
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data, Maine currently has the highest rates among US states, while Utah has the...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it will host a key opinion leader (KOL) webinar to discuss pelareorep in...

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
BRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINE

Brenig Therapeutics, a clinical-stage biotechnology company pioneering AI-powered small-molecule therapies for neurodegenerative diseases, today announced two key executive appointments. David L. Lucchino has been named...

BRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINE
Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND-201 (methylone) for the Treatment of PTSD

Transcend Therapeutics, a clinical-stage biotechnology company that develops medicines to treat neuropsychiatric diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy...

Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND-201 (methylone) for the Treatment of PTSD
Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor...

Kodiak Sciences to Host Investor R&D Day on July 16, 2025
CS Genetics Launches 96-Sample SimpleCell™ Kit, Delivering Same-Day Single Cell RNA-Seq at Population Scale

CS Genetics, a privately held genomics technology company, today announced the commercial launch of its 96-sample SimpleCell 3' Gene Expression Kit, further expanding the capabilities of its SimpleCell platform for...

CS Genetics Launches 96-Sample SimpleCell™ Kit, Delivering Same-Day Single Cell RNA-Seq at Population Scale
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset,...

AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety,...

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Giroir Commends Formation of Congressional BIOTech Caucus

Brett P. Giroir, M.D., former Assistant Secretary of Health and Acting FDA Commissioner in the first Trump Administration, praised the recently announced formation of the bipartisan BIOTech Caucus and noted the critical...

Giroir Commends Formation of Congressional BIOTech Caucus
Spiber Inc. and Iris van Herpen Unite for a Visionary Collaboration at Paris Haute Couture Fashion Week AW2025

At the forefront of high fashion and biomaterial innovation, Japanese biotech venture Spiber, a pioneer in man-made protein fiber, and acclaimed Dutch haute couture designer Iris van Herpen together unveiled one of the...

Spiber Inc. and Iris van Herpen Unite for a Visionary Collaboration at Paris Haute Couture Fashion Week AW2025
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the...

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information

Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition...

$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
NCCN Awards Grants to Improve Care for People with Non-Small Cell Lung Cancer in Collaboration with Taiho Oncology, Inc.

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new funding for advancing clinical research in Non-Small Cell Lung Cancers (NSCLC). Two grants have been awarded to...

NCCN Awards Grants to Improve Care for People with Non-Small Cell Lung Cancer in Collaboration with Taiho Oncology, Inc.
Eirion Therapeutics to Present at the 2025 American Academy of Dermatology Innovation Academy Meeting

Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription products, today announced that the company will present at the 2025 American Academy of Dermatology Innovation...

Eirion Therapeutics to Present at the 2025 American Academy of Dermatology Innovation Academy Meeting
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050,...

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under which Sironax will...

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy...

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and...

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing....

Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio
Biotia Partners with Leading Korean Pharmaceutical Company to Advance Infectious Disease Diagnostics in Remote Regions -- Including in Space

Biotia, a biotechnology company pioneering the development of novel infectious disease diagnostics, today announced its selection as an awardee in the Humans in Space (HIS) Challenge, a global innovation program led by...

Biotia Partners with Leading Korean Pharmaceutical Company to Advance Infectious Disease Diagnostics in Remote Regions -- Including in Space
Aperture, LLC announces the acquisition of Biomechanical Consultants, Inc.

Aperture, LLC ("Aperture"), a Genstar portfolio company, announced today its partnership with Biomechanical Consultants. Founded in 2000 by Sean Shimada, Ph.D. in Davis, California, Biomechanical Consultants provides...

Aperture, LLC announces the acquisition of Biomechanical Consultants, Inc.
Circular Genomics Receives $250K Investment from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer's Disease

Circular Genomics, Inc., a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it has received a $250,000 investment from the Alzheimer's Drug Discovery Foundation...

Circular Genomics Receives $250K Investment from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer's Disease
Mercy BioAnalytics Appoints Dr. Prasanth Reddy as Chief Medical Officer

Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of Prasanth Reddy, M.D. MPH, FACP, as its Chief Medical Officer. Dr....

Mercy BioAnalytics Appoints Dr. Prasanth Reddy as Chief Medical Officer
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer

Cizzle Bio, Inc., a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric cancers, has submitted a grant application to the National Institutes of Health (NIH), in...

Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor...

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen

Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage...

Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued...

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
LakeShore Biopharma Announces US$15 Million Private Placement Financing

LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for...

LakeShore Biopharma Announces US$15 Million Private Placement Financing
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community

UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to raise awareness of...

UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating...

Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection
Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI...

Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities

WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently...

WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States.

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration...

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
INOVIO to Present at Upcoming Scientific Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will...

INOVIO to Present at Upcoming Scientific Conference
Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced the results of the analytical...

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid
Myosin Therapeutics Publishes Two Foundational Studies in the Journal Cell Highlighting a Novel Approach to Treating Cancer and Brain Disorders

Myosin Therapeutics, a clinical-stage biotechnology company advancing first-in-class therapies targeting molecular motor proteins, announced the publication of two major papers in the journal Cell that establish non-muscle...

Myosin Therapeutics Publishes Two Foundational Studies in the Journal Cell Highlighting a Novel Approach to Treating Cancer and Brain Disorders
Lifeforce and Toku Combine AI Retinal Scans with the World's Largest Longevity-Medicine Platform to Take Steps to Slow Aging and Reduce Cardiovascular Risk

Lifeforce, the world's largest longevity medicine platform, and Toku, a health technology company using AI to translate a single retinal image into real-time biological age and cardiovascular risk scores, have...

Lifeforce and Toku Combine AI Retinal Scans with the World's Largest Longevity-Medicine Platform to Take Steps to Slow Aging and Reduce Cardiovascular Risk
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music...

MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society...

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Cyrex Launches BiomeBurden™ for Immune Sensitivity Testing of Microbial, Yeast and Mold Triggers

Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced the launch of BiomeBurden™, its newest innovation in gut biome testing. This advanced 3-panel testing...

Cyrex Launches BiomeBurden™ for Immune Sensitivity Testing of Microbial, Yeast and Mold Triggers
VIOME COLLABORATES WITH MICROSOFT TO DELIVER PREVENTIVE HEALTHCARE WITH ONE OF WORLD'S LARGEST RNA DATASETS

Viome Life Sciences, a leader in AI-powered, RNA-based molecular diagnostics and personalized nutrition, today announced a collaboration with Microsoft to accelerate the next generation of preventive and personalized...

VIOME COLLABORATES WITH MICROSOFT TO DELIVER PREVENTIVE HEALTHCARE WITH ONE OF WORLD'S LARGEST RNA DATASETS
National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease

Under the agreement, the National Heart, Lung, and Blood Institute / National Institutes of Health will perform a human phase I clinical trial of Vascarta's VAS-101 (Vasceptor®; topical curcumin gel) in Sickle Cell...

National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease
WuXi AppTec Receives MSCI ESG AAA Leader Rating

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating –...

WuXi AppTec Receives MSCI ESG AAA Leader Rating
MapLight Therapeutics Announces Initiation of Phase 2 Trial of Its Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Schizophrenia

MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential treatment for schizophrenia....

MapLight Therapeutics Announces Initiation of Phase 2 Trial of Its Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Schizophrenia
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated...

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
Beko Recognised as One of TIME Magazine's Most Sustainable Companies in the World 2025

Leading global home appliance manufacturer Beko has been named one of TIME Magazine's World's Most Sustainable Companies for the second year running, earning a place in the Top 20 and securing the #1 position in...

Beko Recognised as One of TIME Magazine's Most Sustainable Companies in the World 2025
NetDragon Wins "Education Innovation & Technology- Rising Star Award" at the "2025 Hong Kong Sustainable Development Innovation and Technology Awards"

NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 777), a global leader in building internet communities, is pleased to announce that it wins the "Education Innovation & Technology...

NetDragon Wins "Education Innovation & Technology- Rising Star Award" at the "2025 Hong Kong Sustainable Development Innovation and Technology Awards"
Nuevocor Strengthens Board with Appointment of Thierry Abribat

Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors.

Nuevocor Strengthens Board with Appointment of Thierry Abribat
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved...

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options

A new study is the first to examine the application of behavioural science in getting underused therapies for Parkinson's Disease to the patients who need them most.

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options
INOVIO Announces Pricing of $25 Million Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today...

INOVIO Announces Pricing of $25 Million Public Offering
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform

MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE...

MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it has...

So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and...

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it...

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Water Replenishment District Receives Certificate of Achievement for Excellence in Financial Reporting for 21st Consecutive Year

The Water Replenishment District (WRD) has once again been recognized for its commitment to financial transparency, accountability, and reporting. The Government Finance Officers Association (GFOA) has awarded WRD the...

Water Replenishment District Receives Certificate of Achievement for Excellence in Financial Reporting for 21st Consecutive Year
INOVIO Announces Proposed Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today...

INOVIO Announces Proposed Public Offering
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering...

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different...

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response
iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor

iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced the appointment of Prof. Dr. Iris Loew-Friedrich as Clinical and...

iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor
Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancers Congress 2025

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today presented new clinical data from the ongoing STARt-001 Phase 1/2 trial of Invikafusp alfa...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancers Congress 2025
X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event

X-Therma Inc., a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in the prestigious Hopkins on the Hill event, held on June 11, 2025, in...

X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event
mAbxience Announces European Commission Approval of Denosumab Biosimilars

mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This...

mAbxience Announces European Commission Approval of Denosumab Biosimilars
Circulate Health Raises $12 Million in Seed Funding to Accelerate Research in Longevity and Expand Therapeutic Plasma Exchange (TPE) Treatment Centers

Circulate Health, a longevity startup dedicated to harnessing the potential of therapeutic plasma exchange (TPE) to advance human healthspan and lifespan, announced today that it raised $12 million in a seed funding led by...

Circulate Health Raises $12 Million in Seed Funding to Accelerate Research in Longevity and Expand Therapeutic Plasma Exchange (TPE) Treatment Centers
Moon Surgical Receives FDA Clearance for Maestro™ Connectivity and Predetermined Change Control Plan for AI-Powered ScoPilot®

Moon Surgical, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for two major advancements to its Maestro System: connectivity of the platform to power the Maestro Insights product and a...

Moon Surgical Receives FDA Clearance for Maestro™ Connectivity and Predetermined Change Control Plan for AI-Powered ScoPilot®
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive...

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Independent Data Monitoring Committee (IDMC) has...

IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria

More than 1,200 reported cases of CRE (Carbapenem-Resistant Enterobacteriaceae) infections have been reported in the In-cheon region of South Korea alone between January and April of this year. In addition, in June of this...

[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition

Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. and...

Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery

The landscape of metagenomics and microbiome research is evolving at breakneck speed. As sequencing technologies improve and the demand for high-resolution, bias-free microbial data grows, the bottleneck is shifting from...

iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply-while early-onset...

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
ImmunoGenesis Announces the Formation of Scientific Advisory Board

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with...

ImmunoGenesis Announces the Formation of Scientific Advisory Board
SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel

SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A.

SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics

Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, announced today the launch of STAgora™, a next-generation platform for infectious disease analytics. Designed as a real-time infectious disease...

Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
SonoClear AS Receives FDA Breakthrough Designation for SonoClear® System

SonoClear AS today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has designated the SonoClear® System as a Breakthrough Device for use in intracranial...

SonoClear AS Receives FDA Breakthrough Designation for SonoClear® System
Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that...

Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
BioMarin Announces Completion of Acquisition of Inozyme

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately...

BioMarin Announces Completion of Acquisition of Inozyme
Nuravax, Institute for Molecular Medicine to Present Phase 1 Results and Phase 2 Design of Alzheimer's Vaccine AV-1959R at CTAD 2025

Nuravax Inc., a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced today that two oral presentations-the Phase 1 clinical results and the Phase 2 secondary...

Nuravax, Institute for Molecular Medicine to Present Phase 1 Results and Phase 2 Design of Alzheimer's Vaccine AV-1959R at CTAD 2025
Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve...

Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
Apnimed to Participate in Upcoming July Investor Conferences

Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing...

Apnimed to Participate in Upcoming July Investor Conferences
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced...

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering...

Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Frontage Announces Expansion of Business in Canada with New Leadership

As part of the strategy in expanding service offerings across the globe, Frontage Holdings Corporation is pleased to announce the appointment of Dr. Abdul Mutlib as the President of Frontage Laboratories, Canada. Dr....

Frontage Announces Expansion of Business in Canada with New Leadership
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing

On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical...

WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma